Communiqués Orexo AB OTC Markets

Actions

ORXOY

US68616W1027

Temps Différé OTC Markets Autres places de cotation 19:39:53 24/06/2024			Varia. 5j.	Varia. 1 janv.
2 ^USD	+16,28 %		-9,50 %	+32,45 %

08/05	Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024
08/05	Orexo AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Orexo : Presentation	25/06	PU
Orexo : Life Science Investor Forum US, June 20 (Presentation)	14/06	PU
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm	10/05	AQ
Orexo Q1 2024 Interim Report	08/05	AQ
Fentanyl awareness day: The synthetic opioid fentanyl increasingly poisons young Americans	07/05	PU
Orexo : Invitation to presentation of Orexo´s Q1 2024 Interim Report	02/05	PU
Report from Orexo AB's annual general meeting, 26 April 2024	26/04	AQ
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US	17/04	AQ
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled	02/04	AQ
Orexo publishes the Annual and Sustainability Report for 2023	28/03	AQ
Correction: Notice of Annual General Meeting of Orexo	15/03	AQ
Notice of Annual General Meeting of Orexo	15/03	AQ
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds	13/03	AQ
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds	08/03	AQ
Orexo strengthens its sustainability work by establishing a social financing framework	08/03	AQ
Orexo and Sobi agree to advance feasibility study with AmorphOX	12/02	AQ
Orexo Interim Report Q4 2023, incl. Full Year Report	08/02	AQ
Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC	06/02	AQ
Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose	28/11	AQ
Orexo Q3 2023 Interim Report	02/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Orexo AB OTC Markets

Actions

ORXOY

US68616W1027

Communiqués

Filtres